Capital increase in connection with exercise of warrants

In December 2013, Ambu A/S issued 2,000,000 warrants and in December 2014 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme and 22 individuals participate in the 2014 scheme. In both cases, the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 7 May 2018 in connection with Ambu’s interim financial report for Q2 2017/18.

Since 7 May 2018, instructions have been received to exercise warrants as follows:

- 2013 scheme: Two individuals have issued instructions to exercise a total of 100,000 warrants at the agreed exercise price of DKK 13.26 per share with a nominal value of DKK 0.50.
- 2014 scheme: One individual has issued instructions to exercise a total of 140,000 warrants at the agreed exercise price of DKK 23.06 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 120,000 from DKK 125,392,300 to DKK 125,512,300 through the issue of 240,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 200,000 remaining warrants under the 2013 scheme being held by six individuals and 800,000 remaining warrants under the 2014-scheme being held by 11 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 23 May 2018 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

<table>
<thead>
<tr>
<th>Number of shares (nominal value DKK 0.50)</th>
<th>Nominal value (DKK)</th>
<th>Voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>A shares</td>
<td>34,320,000</td>
<td>17,160,000</td>
</tr>
<tr>
<td>B shares</td>
<td>216,704,600</td>
<td>108,352,300</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>251,024,600</strong></td>
<td><strong>125,512,300</strong></td>
</tr>
</tbody>
</table>

Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com
About Ambu
Since 1937, breakthrough ideas have driven our work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and advancing single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ and the legendary Blue Sensor™ electrodes to our latest landmark solutions such as the aScope™ – the world’s first flexible single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu employs approximately 2,500 people in Europe, North America, Asia and the Pacific region. You can find more information about Ambu at www.ambu.com